ERBB2 and viral infectious disease: To ensure that the observed difference in tumor burden was not due to variation in virus infection and therefore oncogene transduction efficiency, we co-expressed HER2/neu with luciferase and measured the total luminescence flux of the injected mammary glands 4 and 8 days after virus injection.